[{"NetIncomeLossConverted_2_Q2_USD":-44200000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":76600000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":77200000.0,"CommonStockSharesConverted_0_Q2_shares":77700000.0,"Assets_0_Q2_USD":1360300000.0,"RevenuesConverted_2_Q2_USD":362500000.0,"RevenuesConverted_1_Q2_USD":189400000.0,"StockholdersEquity_0_Q2_USD":902500000.0,"CommonStockSharesOutstanding_0_Q2_shares":77700000.0,"EarningsPerShareDiluted_2_Q2_USD":-0.58,"EarningsPerShareDiluted_1_Q2_USD":-0.06,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":67400000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":76600000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":77200000.0,"StockholdersEquityConverted_0_Q2_USD":902400000.0,"NetIncomeLossConverted_1_Q2_USD":-4700000.0,"EarningsPerShareBasic_1_Q2_USD":-0.06,"EarningsPerShareBasic_2_Q2_USD":-0.58,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20210804"}]